Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tofacitinib + Meglumine Antimoniate for Cutaneous Leishmaniasis
NCT06011343Phase 3Unknown
- Sponsor
- Hospital Universitário Professor Edgard Santos
- Start
- Oct 2023
- Primary completion
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of tofacitinib oral solution in cutaneous leishmaniasis (CL), sponsored by Hospital Universitário Professor Edgard Santos. Status: unknown.
02
Drugs
tofacitinib oral solution
03
Conditions
cutaneous leishmaniasis (CL)
Beyond the preview
Go deeper on NCT06011343.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06011343.